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Abstract
Background: Immunological and clinical outcomes can vary considerably at the individual and population levels during
both treated and untreated HIV-1 infection. Cytokines encoded by the interleukin-10 gene (IL10) family have broad
immunomodulatory function in viral persistence, and several SNPs in the IL10 promoter sequence have been reported to
influence pathogenesis or acquisition of HIV-1 infection.
Methodology/Principal Findings: We examined 104 informative SNPs in IL10, IL19, IL20, IL24, IL10RA and IL10RB among 250
HIV-1 seropositive and 106 high-risk seronegative African American adolescents in the REACH cohort. In subsequent
evaluation of five different immunological and virological outcomes related to HIV-1 infection, 25 SNPs were associated with
a single outcome and three were associated with two different outcomes. One SNP, rs2243191 in the IL19 open reading
frame (Ser to Phe substitution) was associated with CD4
+ T-cell increase during treatment. Another SNP rs2244305 in IL10RB
(in strong linkage disequilibrium with rs443498) was associated with an initial decrease in CD4
+ T-cell by 2369% and
2969% every 3 months (for AA and AG genotypes, respectively, compared with GG) during ART-free period. These
associations were reversed during treatment, as CD4
+ T-cell increased by 3160.9% and 1768% every 3 months for AA and
AG genotype, respectively.
Conclusions/Significance: In African Americans, variants in IL10 and related genes might influence multiple outcomes of
HIV-1 infection, especially immunological response to HAART. Fine mapping coupled with analysis of gene expression and
function should help reveal the immunological importance of the IL10 gene family to HIV-1/AIDS.
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Introduction
The IL10 gene has been implicated in HIV-1 infection and
pathogenesis in numerous studies [1,2,3,4]. IL-10 is a cytokine
produced mainly by TH2 cells and occasionally by activated B-
cells, TH1 cells, activated macrophages, and nonhematopoietic
cells (e.g., keratinocytes) [5,6]. It has a uniquely broad immuno-
modulatory effect, especially in suppressing cell-mediated immu-
nity through down-regulating pro-inflammatory cytokines, co-
stimulatory molecules, as well as major histocompatibility complex
(MHC) class II proteins. Animal models suggest that IL-10 plays a
significant role in viral persistence[7] in general and has specific
effects on HIV-1 infection through T-cell activity [8,9]. IL-10-
positive CD8
+ T cells have a regulatory role in the immune
dysfunction of HIV-1 infection [10]. IL-10 levels are greater in
HIV-1-positive individuals with declining CD4
+ T-cell and high
HIV-1 viral loads than in newly infected individuals[11]. In
contrast, long-term non-progressors have low IL-10 levels
comparable to HIV-1-negative individuals. The HIV-1 regulatory
protein, Tat, has also been shown to induce IL-10 production
[12]. Higher concentrations of IL-10 appear to limit HIV-1
replication in vivo by inhibiting macrophages/monocytes and T-
cell lymphocyte replication [13,14,15,16], and administration of
IL-10 to HIV-1-positive patients has also been shown to decrease
the number of circulating HIV-1 virions [17]. IL-10 inhibition of
T-cell apoptosis could actually be beneficial for HIV-1-infected
individuals [18]. IL-10 may also selectively up-regulate the
expression of the CC chemokine receptors CCR5, CCR2 and
CCR1 in human monocytes [19,20,21]; these control entry of the
virus into the cell. Further, several studies indicate that IL-10
production is induced in vivo [22] and in vitro [23] during HIV-1
infection.
The association between SNPs in IL10 and HIV-1 pathogenesis
or infection has received considerable attention, but the impor-
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analysis [24], European Americans carrying the A allele at the
2592 position (rs1800872) of IL10 promoter were at increased risk
for HIV-1 infection (OR=1.75, p=0.03). Investigators in that
same study suggested that 25–30% of untreated, long-term non-
progressors (.10 years without AIDS) among European Ameri-
cans could be explained by the presence of the wild-type
rs1800872 C/C genotype. Additional IL10 variants have also
been associated with disease progression to AIDS [2,24,25], often
with inconsistent conclusions.
Selective adaptation of polymorphisms within IL10 in different
populations has resulted in semi-conserved regions and generated
these adjacent paralogs that may have entirely or only partially
redundant or antagonistic functional properties. IL19, IL20, and
IL24 are located upstream of the IL10 gene within the cytokine
gene cluster in a 200 kb region on chromosome 1q31–32 (Figure
S1). The four genes have similar intron–exon structures and they
form a subfamily based on similar protein sequences, cellular
sources (i.e., activated immune cells, including monocytes), and
receptors on target cells. Several functional and biological
interactions are known between these paralogs. For example, IL-
19 stimulation can increase its own expression and IL10 mRNA
transcription, while IL-10 potently down-regulates the ‘autoinduc-
tion’ of IL-19 [26,27]. Upregulation of IL-19 and IL-20 has been
found following in vitro stimulation of mammary and amniotic
epithelial cells with extracellular HIV-1 Tat [28]. Similarly, IL-10
utilizes the JAK-STAT pathway for downstream signaling, and the
paralogs IL-19 and IL-20 have capacity to induce phosphorylation
of STAT1 or STAT3 or both [29]. Overall, immune regulation
mediated by the IL10 gene family can influence HIV-1
pathogenesis through multiple mechanisms. Genotypes of IL10
and the evolutionarily conserved regulatory regions encoded by
the related gene sequences could become useful biomarkers if their
relationships to HIV-1 infection and disease progression with our
without treatment are unambiguously established. Here, we
hypothesize that involvement of the IL-10 molecule in HIV-1
infection and pathogenesis could be modulated through complex
interactions among IL10 and its related genes, especially those
(IL19, IL20 and IL24) in the flanking genomic region and the IL-
10 receptor genes (IL10RA and IL10RB).
Materials and Methods
Ethics Statement
The parent study and this sub-study conformed to the
procedures for informed written consent (parental permission
was obtained wherever required) approved by institutional review
boards (IRB) at all sponsoring organizations and to human-
experimentation guidelines set forth by the United States
Department of Health and Human Services and finally reviewed
and approved by the UAB IRB.
Study population
We studied 356 eligible African American participants from the
Reaching for Excellence in Adolescent Care and Health (REACH)
study. The characteristics of the cohort, recruitment, follow-up
and research objectives are described in detail elsewhere [30,31].
Briefly, REACH is an observational study of 352 HIV-1
seropositive (based on self-report vertical transmissions were not
included) and comparable 196 high-risk seronegative adolescents
(13 to 19 years old) recruited from 15 clinical sites in 13 US cities
between 1996 and 1998 and followed until 2001. The cohort
comprised 71% African Americans and 76% females. All subjects
designated uninfected for this study had a history of either sexual
intercourse or injection drug use, had a negative HIV-1 enzyme
linked immunosorbent assay (HIV-1-ELISA) performed within 30
days of enrollment into REACH, and remained seronegative until
the end of the study period. All infected subjects had a positive
ELISA, with a confirmatory Western blot performed before
REACH enrollment. Participants were followed on a quarterly
basis for epidemiologic, clinical, and laboratory evaluations,
including documentation of demographic and risk behaviors,
collection of medical history and various biological samples, along
with tests for HIV-1 infection, other sexually transmitted
infections, CD4
+ T-cell, and immunological outcomes. HIV-1
RNA concentration (viral load, VL) and immunological outcomes
were measured every three months. CD4
+ T-lymphocytes were
quantified by flow cytometry in National Institute of Allergy and
Infectious Disease (NIAID)-certified laboratories at each clinical
site. Viral load (VL) was measured in a centralized laboratory
using either nucleic acid sequence-based amplification (NASBA,
lower limit detection =400 copies/mL) or NucliSens assays
(Organon Teknika, Durham, NC, lower limit =80 copies/mL).
Only two individuals seroconverted during follow-up of REACH
and all others were HIV-1 seropositive at baseline (enrollment). In
most cases, duration of infection, as inferred from young age
(median at 17), self-reported sexual debut (not earlier than age 13),
and other risk behaviors (no vertical transmission), should be no
more than five years when viral load measures were taken. As a
result, stable VL at two or more clinical visits was treated as a
proxy for VL set-point [30,32].
Study design
To minimize confounding by population stratification, our
analyses were restricted to the subset of African Americans. Small
numbers representing additional ethnic groups (Hispanics, Euro-
pean Americans, and others or unknown) were not tested because
of limited statistical power.
HIV-1 infection
We analyzed 250 HIV-1 seropositive (199 females and 51
males) and 106 high-risk seronegative (84 females and 22 males)
African American adolescents.
Viral load set-point
As we previously described [33], viral load set-point was
estimated using the covariance structure model of the first 2–4
sequential viral load measures across individual participants. We
included each individual as a random effect variable and excluded
the visits where the subsequent viral loads did not appear to be in
steady state, i.e. inter-visit viral load variation exceeded 0.5 log10
copies per ml of plasma. Of the 250 HIV-1-positive African
American subsets, 121 (102 females and 19 males) had VL
set-point.
Categorical Disease Progression
Three ordinal patient groups were classified according to
longitudinal immunological and virological data: 26 participants
were defined as ‘‘controllers’’ (VL,1000 copies/ml and CD4
+ T-
cell .450610
6 cell/l), 36 as ‘‘non-controllers’’ (VL.16,000
copies/ml, CD4
+ T-cell ,450610
6 cell/l), and 99 as ‘‘interme-
diates’’ [34].
CD4
+ T-cell trajectories
The availability of longitudinal CD4
+ T-cell provided the
opportunity to determine the influence of genetic variants on
CD4
+ T-cell slope during antiretroviral therapy (ART)-free and
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+ T-cell
trajectory among 148 individuals during ART-free visits (median
visit =4 [IQR 3–8]). Next, we assessed the CD4
+ T-cell trajectory
among169 adolescents during the period that they received
HAART with self-reported adherence (median visit =5 [IQR
3–9]) [30]. All AIDS-free individuals who had follow-up data
during at least 2 consecutive visits were included in the analyses.
Consistent with the Public Health Service Guidelines for the Use
of Antiretroviral Agents in HIV-Infected Adults and Adolescents
[35], participants who were prescribed a combination of two
nucleoside reverse transcriptase inhibitors and either a protease
inhibitor, or a non-nucleoside reverse transcriptase inhibitor, or a
zidovudine/lamivudine combination regimen plus another anti-
retroviral drug, at the time of a study visit were considered eligible
for analysis. Data on HAART were obtained through interviews
and chart reviews for past and current prescriptions, and
adherence data were obtained through interviews, as described
elsewhere [36]. All participants were censored at the last available
visit (including end of study) or the first visit that they reported not
adhering to HAART regimen. Individuals who did not receive
HAART were excluded even if they received suboptimal
treatment. Of note, a subset of ART-naive individuals with
adequate follow-up started HAART during the later phase of
study and they were also eligible for analyses of HAART-induced
changes in CD4
+ T-cell slope.
Genotyping
High-molecular-weight genomic DNA extracted from whole
blood was used for the genotyping of 115 SNPs throughout the
coding and UTR regions, including haplotype tagging-SNPs in
introns of IL10 and related genes for three paralogs (IL19, IL20
and IL24), and two receptor (IL10RA and IL10RB). The custom
GoldenGate assay (Illumina, San Diego, CA) and iPLEX assay
(Sequenom massarray) were done using two commercial platforms
(Illumina, San Diego, CA and Broad Institute, Cambridge, MA).
Analyses of SNP genotypes
Hardy-Weinberg equilibrium (HWE) was examined for each
SNP. Pairwise linkage disequilibrium (LD) was quantified using
the absolute value of Lewontin’s D’ and r
2 and LD plots were
generated using Haploview version 4.1 [37]. Separate analyses
were conducted for each outcome of the HIV-1 pathogenesis
stages and only previously confirmed and validated (in other
cohorts) genetic and non-genetic factors were adjusted for in the
analyses.
Chi-square tests were used to assess the distribution of alleles
and genotypes between HIV-1-positive and HIV-1-negative high-
risk adolescents and all significant associations (p,0.05) were
further evaluated accounting for non-genetic factors age, gender
and number of sex partners as previously described [38]. For
analysis of VL set-point, we estimated mean VL [39] by genotype
at each SNP, and also accounted for the confirmed HLA-B57
effect [33] and multiple comparisons using Tukey-Kramer
adjustment. We also determined the allelic and genotypic
heterogeneity among controllers, non-controllers, and intermedi-
ates controllers, as defined previously [34]. Categorical outcomes
were assessed by x
2 and Cochran-Armitage trend tests and
analyses were also performed separately for HLA-B57 negative
individuals since this was such a strong marker in previous
analyses.
Changes in CD4
+ T-cell over time were assessed using the linear
mixed random effects models assuming a Poisson regression for
CD4
+ T-cell where the parameter l is the expected value or mean
of the distribution. From the definition of the distribution, this
parameter must have a positive value, so a regression model was
set up in log function as follows: log(l)=b0 + b1x1+ b2x2 for the
case of two predictor variables where l = exp (b0 + b1x1+ b2x2)
and subsequently, Bi = exp (bi) for i =0, 1, 2 and the count
predicted by the model is given by l~B0B
x1
1 B
x2
2 . Therefore, an
increase in x1 of one unit causes the expected count to be
multiplied by B1 = exp (b1), and similarly an increase of one unit
of x2 causes the expected count to be multiplied by B2 = exp (b2).
These models accounted for the correlation between serial
measurements at consecutive visits from each person and were
implemented using the Proc routine in SAS. To account for any
variability in the trajectory based on the initial CD4
+ T-cell, the
model included an adjustment for baseline CD4
+ T-cell.
Additionally, to account for the potential confounding effects of
HAART, we fit the random effects model separately for both
treatment-free intervals and treatment time periods. All statistical
analyses were limited to univariate model and were performed
using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Of the 115 SNPs with genotyping results, six did not meet HWE
and 5 had minor allele frequency less than 2%, leaving 104
informative SNPS (15 in IL10,2 3i nIL19,1 3i nIL20,9i nIL24,
18 in IL10RA and 26 in IL10RB). Patterns of LD (r
2) are shown for
these SNPs in IL10 and neighboring paralogs at chromosome
1q31–32 (Supplementary Figure S1a), IL10RA at 11q23 (Supple-
mentary Figure S1b) and IL10RB at 21q22 (Supplementary Figure
S1c).
HIV-1 Infection
One SNP in IL10RB (rs2266590 in intron; 4 p=0.05) and one
in IL20 (rs2981572 in 59UTR; p=0.006) were associated with risk
of HIV-1 infection (Table 1). In particular, a protective effect was
associated with minor allele of rs2981572 (OR=0.5 [CI: 0.21–
0.94], p=0.006). Even after adjusting for the non-genetic factors,
age, sex and number of sex partners, the effect of this SNP was
strongly protective.
HIV-1 Viral Load Set-point
Three SNPs in IL10 (rs1800890, rs2222202 and rs1878672,
with the latter two in LD) were associated with significant
differences in mean VL in the univariate model by genotype
(Table 2, p,0.005–0.04). Specifically, the mean VLs were –log
3.74 (60.09), 3.51 (60.11), and 2.82 (60.36) cp/ml for TT, AT,
and AA genotypes respectively for rs1800890. For the two SNPs in
LD (represented by rs2222202 based on the more complete
genotype data), the mean VLs were –log10 3.76 (60.10), 3.55
(60.10), and 2.85 (60.26) cp/ml for GG, AG, and AA genotypes
respectively (p=0.03 for trend). After adjusting for the HLA B*57
effect as previously reported [33], rs2222202 (rs1878672) still had
significant effect (p=0.02) where the mean VLs were –log10 3.40
(60.13), 3.24 (60.10), and 2.65 (60.26) cp/ml for GG, AG, and
AA genotypes, respectively.
Categorical Disease Progression
As shown in Figure 1, associations (p=0.0008–0.03) were
observed for genotype trend test among the three patient groups
with two SNPs in the 39 UTR and one SNP in the 59 UTR of IL20
(rs1518108, rs11808756, rs3024523, where the first 2 were in LD,
r
2.0.90) and b) three SNPs in the 59 UTR of IL24 (rs4845147,
rs6540701, rs1856748, where all were in complete LD). Interest-
ingly, it seems that the controllers had a higher frequency (0.12) of
CC genotype for rs3024523, which is rare or absent in the other
IL10 Related Genes and HIV-1
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‘‘controllers’’) were excluded from analysis, there were still
statistically significant trends for differential SNP genotype
distributions across the three ranked patient categories (‘‘control-
lers’’ to ‘‘intermediates’’ to ‘‘non-controllers’’).
Rates of CD4
+ T-cell change
Among the AIDS-free untreated adolescents, the CD4
+ T-cell
trajectory from one visit to the next in the absence of any ART
therapy (i.e. every 3 months on average) was associated with
multiple SNP genotypes. Five SNPs in IL19 (rs908704, rs4845143,
rs2243174, rs2243188, rs2243193, where the first 2 and the latter
3 were in LD, r
2.0.90), one in IL24 (rs291111), one in IL10RA
(rs2244305), and 2 in IL10RB (rs2244305, rs2243498) showed
significant differences (Table 3 top panel). Of note, rs29111 had
the greatest changes where the CD4
+ T-cell decreased by
62618% and 66619% per 3 months for genotypes TT and
TC, respectively, compared to CC.
In the 169 individuals with multiple treated visits, the CD4
+ T-
cell trajectory in response to therapy deviated significantly by
multiple SNP genotypes (Table 3 bottom panel). In particular, one
SNP in IL10 (rs3024496), one in IL19 (rs2243191), two in IL24
(rs291107, rs291109), and two in IL10RB (rs2244305, rs2243498
in LD) showed statistically significant differences in the CD4
+ T-
cell trajectory over time with HAART. A known functional SNP,
rs2243191 (encoding a Phe to Ser substitution) in exon 1 of IL19
showed a change where the CD4
+ T-cell increased by 21610%
and 1966% cells every 3 months for genotypes TT and TC,
respectively, compared to CC, suggesting a dominant effect.
Overall, polymorphisms in six related genes could be associated
with five HIV-1-related outcomes in our study population
(Table 4).
Discussion
Our study suggests that variants within the IL10 gene pathway
might influence various immunological and virological outcomes
of HIV-1 infection and immunological response to HAART in
African Americans. Most genetic associations with immunological
and virological outcomes of HIV-1 infection have been studied in
populations of European descent; relatively fewer have been
evaluated in minority populations, especially African Americans,
where the HIV-1/AIDS epidemic is disproportional. We observed
multiple variants in the potential pathway of the IL10 gene family,
contributing individually or jointly to the heterogeneity in HIV-1
pathogenesis. These potential joint contributions demonstrate the
Table 1. Frequency distribution of genotypes in IL10 related genes between HIV-1
+ and high risk HIV-1
2 adolescents.
Gene and SNP (rs#) Frequencies Genotype Allelic p-value Trend p-value
HIV-1
+ vs HIV-1
2
N=(250) (106) p adjusted-p
*
IL10RB
rs2266590 0.05 0.01
AA 0.10 0.06 0.03 0.07
AG 0.45 0.36 0.04 0.06
GG 0.45 0.59 -
IL20
rs2981572 0.006 0.003
TT 0.15 0.30 0.0009 0.006
TG 0.52 0.45 0.03 0.05
GG 0.33 0.25 - -
*adjusted for gender, age at baseline and life-time sex partner.
doi:10.1371/journal.pone.0013384.t001
Table 2. Difference in viral-load set-point by genotype in IL10 gene family.
Gene and SNP (rs#) Genotype (n) -log10 VL (cp/ml) mean(±std) p-value
adjusted
*
mean(±std)
adjusted
*
p-value
IL10
rs1800890 AA (5) 2.42 (60.36) 0.001
AT (46) 3.51 (60.11) 0.01 ns
TT (70) 3.74 (60.09) -
rs2222202 AA (9) 2.93 (±0.25) 0.008 2.65 (±0.25) 0.02
(rs1878672) AG (50) 3.55 (±0.10) 0.03 3.24 (±0.12) 0.08
GG (62) 3.74 (±0.10) - 3.40 (±0.13) -
rs2222202 and rs1878672 are in LD (r
2=1) and the data are presented for rs222202 with more complete genotype data; ns= not statistically significant.
*adjusted for HLA-B57.
doi:10.1371/journal.pone.0013384.t002
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netic studies either in conjunction with or even instead of analyses
of single candidate genes or hypothesis free genome-wide
association studies. We have examined various HIV-1/AIDS
outcomes and reported several SNPs or combinations that might
play complex immunological roles at various stages of HIV-1
pathogenesis.
Notably, one nonsynonymous SNP (rs2243191) that causes Ser
to Phe substitution in the IL19 open reading frame was associated
with CD4
+ T-cell trajectory during HAART. While the function
of this amino acid change is still unclear, differential allelic
expression combined with its function in TH2 pathway [40] may
provide some basis for the epidemiologic findings here. Other
SNPs of interest have no immediate evidence for functional
properties, but their importance to gene expression (translation
and mRNA stability) cannot be ruled out. Sequence alignments of
human IL10 gene and its paralogs indicate numerous regions of
close homology with other species. Such conserved non-coding
sequences are known to contain regulatory elements. Bioinfor-
matics coupled with experimental approaches may eventually
reveal the intrinsic connection between non-coding SNPs and
gene function.
Associations of these different SNPs in different members of a
‘‘gene family’’ with different phenotypes of HIV-1 infection raise
concern about whether the effects are of true biologic significance
or are more likely to have been spuriously introduced by multiple
comparisons. To avoid the latter pitfall, rather than perform
multivariable, haplotype or interaction analyses that might well be
underpowered in our relatively small cohort, we have only
reported univariate analyses and only with adjustment for
confirmed non-genetic and genetic factors, thereby presenting
only a broad overview of possible associations of the IL10 gene
family with HIV-1 pathogenesis. Overall, associations with at least
three SNPs could withstand Bonferroni correction for multiple
(10465=520) tests (corrected cut-off p#9.6610
25). Some of the
marginal associations (in terms of borderline statistical significance
levels based on relatively small sample sizes) may have been
detected by chance. However, they may still provide valuable
benchmarks to benefit future research, especially since the six
genes have not been fully studied in any population with HIV-1
infection.
The results even from a small sample-size could possibly suggest
several avenues of future inquiry. First, different genes within the
IL10 family are expected to function in different stages of HIV-1
pathogenesis. The preservation of IL10 gene paralogs and other
functionally related genes is likely the result of co-evolution,
through which they act optimally in concert to confer biological
effects, specifically in the context of infections with agents like
HIV-1 where the antigenic repertoire evolves rapidly within the
host. Second, the role of these genes may change as HIV-1
infection reaches different stages (acquisition, acute and early
controlled, chronic and late progression). Selective analysis of
known ‘‘tagging’’ SNPs in the context of one phenotype (e.g., VL)
at a time is less likely to reveal more comprehensive and complex
relationships. Third, involvement of the IL-10 product in
immunity to HIV-1 infection could be modulated through more
complex interactions among related genes that may not be
physically close but occur within the same biological system. For
example IL22, IL26, IL28 and IL29 can also use the IL10RB
receptor [41]. Fourth, some of the SNPs we found associated with
HIV-1 outcomes are polymorphic only in African-Americans. For
example, three informative SNPs (Table 4) in our study population
have been reported as non-polymorphic in the European
American population, implicating the need to study different
Figure 1. SNPs in IL10 gene family associated with the combined immunological and virological control of HIV infection. Genotype
frequencies are compared for all ‘‘controllers’’ (CLs), ‘‘intermediate controllers’’ (IntCL) and ‘‘non-controllers’’ (NCL) as defined by virological and
immunological markers. Two SNPs in IL20 (rs1518108 and rs11808752) are in LD (r
2=0.90) and data is presented for rs1518108 with more complete
data; rs4845147, rs6540701 and rs1856748 in IL24 are in LD (r
2=0.91) and data are presented for rs4845147 with more complete data; p-value is
presented for all individuals including and excluding 12 HLA-B57+ individuals.
doi:10.1371/journal.pone.0013384.g001
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era, we have heavily relied on genome-wide association studies
(GWAS) and the reported SNPs in the commercial genotyping
arrays. However, of the 25 SNPs that were found to be
significantly associated with different outcomes in our study
(Table 4), only nine are present in the Human 1M-Duo chip
(Illumina) and only 6 are present in the Affy 6.0 chip (Affymetrix),
and only one is present in both panels. In other words, even the
most current GWAS arrays could not sufficiently survey
potentially important SNPs even if they are used in combination.
More recently, GWAS has revealed that one IL10 SNP
(rs4072227) out of 14 examined was associated with HIV-1 VL
set-point (adj p=0.03) in the European American component
[42], but no associations surfaced in the African Americans.
Further, rs4072227 does not seem to be in LD with any functional
SNP in the region in any of the HapMap populations. Finally, we
have noted that other immune response genes reside in the
neighborhood of IL10 and related candidate genes selected for our
work. In particular, MAPKAP2 is only 35 kb away from the
promoter of IL10, and some of the candidate SNPs in the former
gene (mostly in noncoding sequences) may well tag other variants
important to microRNA function, DNA methylation and/or gene
expression.
As more detailed information about the genome becomes
available, many of the poorly understood regulatory elements
(SNPs in introns, 59 and 39UTRs) may be shown to exert more
significant functional effects. Thus, reports from association
studies like the present one on the IL10 gene family as well as
other genes and their related families should be weighed in the
context of what is known about the biologic pathways that
influence the pathogenesis of HIV-1 infection. Both population
and experimental studies will be needed to evaluate the
r e l e v a n c eo fp o l y m o r p h i s mt og e n ee x p r e s s i o na n di m m u n e
response.
Table 3. Influence of IL10 gene family genotypes on CD4
+ T-cell trajectory during a) ART-free period (n=148) and b) HAART
(n=169).
Gene and SNP (rs#) Genotype (n) CD4
+ decline ±95% CI (% decrease every 3 months) p-value
ART-Free
IL19
rs908704 AA (17) 23168 0.0002
(rs4845143) AG (60) 21968 0.02
rs2243174 AA (25) 23167 2.9*10e
25
(rs2243188) AG (69) 21767 0.02
(rs2243193)
IL24
rs291111 TT (8) 262619 0.001
TC (56) 26669 0.0008
IL10RA
rs9610 AA (18) 22969 0.002
AG (58) 22469 0.009
IL10RB
rs2244305 AA (23) 22369 0.008
(rs2243498) AG (69) 22969 0.001
On HAART
IL10
rs3024496 TT (18) 23610 0.03
TC (73) 3169 0.002
IL19
rs2243191 TT (7) 21610 0.04
TC (53) 1966 0.004
IL24
rs291107 AA (7) 56612 1.9*10e
26
AG (50) 2066 0.0004
rs291109 AA (12) 2068 0.008
AG (46) 2766 2.3*10e
25
IL10RB
rs2244305 AA (23) 3169 0.0003
(rs2243498) AG (69) 1768 0.02
rs908704 and rs4845143 are in LD (r
2=0.91) and data are presented for rs908704, which has more complete data; rs2243174, rs2243188 and rs2243193 are in LD
(r
2.0.90) and data are presented for rs2243174, which has more complete data; rs2244305 and rs2243498 are in LD (r
2.0.94) and data are presented for rs2244305,
which has more complete data.
doi:10.1371/journal.pone.0013384.t003
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Figure S1 Pairwise linkage disequilibrium (r
2) measures for
informative SNPs in a) IL10, IL19, IL20 and IL24 (chromosome
1q31-32), b) IL10RA (chromosome 11q32), and c) IL10RB
(chromosome 21q22.11).
Found at: doi:10.1371/journal.pone.0013384.s001 (0.58 MB TIF)
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